The development of semaglutide from an engineered GLP-1 analogue in the laboratory to a globally approved, first-line therapy for diabetes and obesity illustrates the power of modern translational pharmacology. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.